Source-grounded facts extracted from ROCKET PHARMACEUTICALS, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
ROCKET PHARMACEUTICALS, INC. reported the first quarter ended March 31, 2026 results: net income Net loss was $47.6 million or $0.42 per share (basic and diluted) for the three months ended March 31, 2026, EPS $0.42 per share (basic and diluted).
“Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today reported financial and recent operational results for the first quarter ended March 31, 2026.”
Material Agreements
ROCKET PHARMACEUTICALS, INC. entered into PRV APA valued at $180 million (effective 2026-04-26).
“On April 26, 2026, Rocket Pharmaceuticals, Inc. (the “Company”) entered into a definitive asset purchase agreement (the “PRV APA”) pursuant to which the Company has agreed to sell a Rare Pediatric Disease Priority Review Voucher (“PRV”).”
Material Agreements
ROCKET PHARMACEUTICALS, INC. terminated Prior Sales Agreement with Cowen and Company, LLC, an affiliate of TD Securities (USA) LLC (effective 2026-03-10).
“Upon entry into the Sales Agreement, the Company terminated its prior “at-the-market” sales agreement with Cowen and Company, LLC, an affiliate of TD Securities (USA) LLC, dated February 28, 2022, (the “Prior Sales Agreement”), as amended by Amendment No. 1 to the Prior Sales Agreement, dated as of September 12, 2023 (“Amendment No. 1”), pursuant to which the Company could offer and sell, from time to time through Cowen and Company, LLC, as its agent, shares of the Company’s common stock.”
Material Agreements
ROCKET PHARMACEUTICALS, INC. entered into Sales Agreement with Cantor Fitzgerald & Co. valued at $100,000,000 (effective 2026-03-10).
“On March 10, 2026, Rocket Pharmaceuticals, Inc. (the “Company”) entered into a sales agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. (the “Sales Agent”), with respect to an at-the-market offering program pursuant to which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.01 per share, having an aggregate offering price of up to $100,000,000 (the “Shares”), through the Sales Agent.”
Restructurings & Charges
ROCKET PHARMACEUTICALS, INC. announced a restructuring with charges of approximately $3.5 million (approximately 30%).
“The Company began notifying affected employees on July 23, 2025, and expects the RIF to be completed by August 8, 2025. The Company estimates that it will incur approximately $3.5 million in restructuring and restructuring-related charges in the second half of 2025 in connection with the Plan, consisting primarily of employee severance payments and other”
R. Keith Woods departed as Director at ROCKET PHARMACEUTICALS, INC..
“On April 26, 2025, R. Keith Woods informed the board of directors (the “Board”) of Rocket Pharmaceuticals, Inc. (the “Company”) that he has accepted a Chief Operating Officer position with a biopharmaceutical company and therefore has decided not to stand for re-election to the Board at the Company’s upcoming 2025 annual meeting (the “2025 Annual Meeting”).”
Sarbani Chaudhuri was appointed as Chief Commercial & Medical Affairs Officer at ROCKET PHARMACEUTICALS, INC..
“On April 7, 2025, Sarbani Chaudhuri was appointed by Rocket Pharmaceuticals, Inc. (the “Company”) as the Company’s Chief Commercial & Medical Affairs Officer.”
Piratip Pratumsuwan was appointed as Director at ROCKET PHARMACEUTICALS, INC..
“On January 25, 2025, the Board, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Piratip Pratumsuwan to the Board, effective January 27, 2025.”
Naveen Yalamanchi resigned as Director at ROCKET PHARMACEUTICALS, INC..
“On January 25, 2025, Naveen Yalamanchi resigned from the Board of Directors (the “Board”) of Rocket Pharmaceuticals, Inc. (the “Company”), effectively immediately.”
Dr. Mikael Dolsten was appointed as Director at ROCKET PHARMACEUTICALS, INC..
“appointed Dr. Mikael Dolsten, M.D., Ph.D. to the Board, effective September 9, 2024.”
Earnings Releases
ROCKET PHARMACEUTICALS, INC. reported preliminary financial results for the quarter ended March 31, 2024.
“On May 6, 2024, Rocket Pharmaceuticals, Inc. (the “Company”) announced certain preliminary financial information for the quarter ended March 31, 2024.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.